Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Reattempts Guidance On Third-Party 510(k) Review Program

Executive Summary

FDA is again attempting to outline its thinking on the 510(k) third-party review program in a new draft guidance. The program, which allows accredited organizations to conduct 510(k) reviews for certain products, has had a lackluster performance since it was first mandated by Congress in 1997.

You may also be interested in...

Senate, House Panels Release Clean Device User-Fee Discussion Draft

Lawmakers emphasized the need for a swift reauthorization of a combined US FDA device and drug user-fee reauthorization bill before the end of July, and released a clean discussion draft April 14 that mirrors the agreements reached by industry and the agency last summer.

Must-Do Guidance Development: What's On Tap From Cures, MDUFA IV

US FDA's device center is facing new mandates and commitments to develop guidelines for industry. The guidance-development stipulations in the 21st Century Cures Act and the recent MDUFA IV user-fee agreement are detailed below.

Global Regulatory Guidelines: Medtech Guidance Tracker, Sept.-Oct. 2016

Stay up-to-date on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. In the latest update, documents posted in September and October 2016.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts